Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 2.96 B
The data is delayed by 15 minutes.
Description: Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment?s oral dose forms include soft gel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development & Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scient
|Shares Outstanding||124.71 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-14.05%||Sales Growth - Q/Q||-2.02%||P/E|
|P/E To EPS Growth||P/S||1.61||P/BV||6.33||Price/Cash Per Share|
|Price/Free Cash Flow||53.01||ROA||2.88%||ROE||18.13%||ROI||3.43%|
|Current Ratio||1.79||Quick Ratio||1.4||Long Term Debt/Equity||6.45||Debt Ratio||0.77|
|Gross Margin||33.9%||Operating Margin||14.77%||Net Profit Margin||4.66%||Dividend Payout Ratio|
|Cash From Financing Activities||209 M||Cash From Investing Activities||-240.3 M||Cash From Operating Activities||94.7 M||Gross Profit||152.2 M|
|Net Profit||31.5 M||Operating Profit||65.8 M||Total Assets||2.97 B||Total Current Assets||653.1 M|
|Total Current Liabilities||365.4 M||Total Debt||1.88 B||Total Liabilities||2.51 B||Total Revenue||446.6 M|
|High 52 week||58.05||Low 52 week||29.84||Last close||57.19||Last change||0%|
|RSI||58.49||Average true range||1.67||Beta||1.08||Volume||419.58 K|
|Simple moving average 20 days||2.98%||Simple moving average 50 days||7.76%||Simple moving average 200 days||32.85%|
|Performance Week||3.81%||Performance Month||5.4%||Performance Quart||27.74%||Performance Half||44.02%|
|Performance Year||41.88%||Performance Year-to-date||83.42%||Volatility daily||1.7%||Volatility weekly||3.79%|
|Volatility monthly||7.77%||Volatility yearly||26.92%||Relative Volume||271.85%||Average Volume||738.2 K|
|New High||New Low|
2019-09-13 08:34:14 | Does Catalent NYSE:CTLT Have A Healthy Balance Sheet?
2019-09-06 09:40:01 | JAZZ vs. CTLT: Which Stock Is the Better Value Option?
2019-09-04 09:15:01 | Lannett LCI Hits 52-Week High, Can the Run Continue?
2019-09-02 09:00:01 | Catalent CTLT Upgraded to Buy: Here's Why
2019-08-30 08:48:44 | Edited Transcript of CTLT earnings conference call or presentation 27-Aug-19 12:15pm GMT
2019-08-28 14:42:17 | Catalent Analyst Cites Valuation Concerns In Downgrade
2019-08-27 16:20:24 | This Surging Medical Stock Beats Views, But Shares Take A Breather
2019-08-27 12:23:29 | Catalent Inc CTLT Q4 2019 Earnings Call Transcript
2019-08-27 08:55:12 | Catalent CTLT Surpasses Q4 Earnings and Revenue Estimates
2019-08-27 07:48:02 | Catalent Reports Q4 Earnings Beat
2019-08-27 07:30:00 | Catalent, Inc. Reports Fourth Quarter Fiscal 2019 Results
2019-08-26 14:35:13 | Catalent's Q4 Earnings Outlook
2019-08-26 13:13:03 | What Are Analysts Saying About Catalent, Inc.'s NYSE:CTLT Growth?
2019-08-21 06:11:09 | Read This Before Judging Catalent, Inc.'s NYSE:CTLT ROE
2019-08-20 10:30:02 | Earnings Preview: Catalent CTLT Q4 Earnings Expected to Decline
2019-08-19 10:10:02 | Medtronic MDT to Post Q1 Earnings: Will RTG Aid the Stock?
2019-08-16 10:49:02 | Medtronic MDT to Report Q1 Earnings: What's in Store?
2019-08-09 10:42:02 | Tilray TLRY to Report Q2 Earnings: What's in the Cards?
2019-08-07 18:32:20 | Novavax looks to next flu vaccine trial following sale of manufacturing business
2019-07-31 10:10:02 | Why Catalent CTLT is Poised to Beat Earnings Estimates Again
2019-07-24 14:45:36 | 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar
2019-07-17 16:15:00 | Catalent, Inc. Announces Fourth Quarter Fiscal Year 2019 Earnings Conference Webcast
2019-07-15 09:30:01 | CTLT vs. ZTS: Which Stock Is the Better Value Option?
2019-07-12 13:42:00 | Here's Why Catalent Stock Soared 73.9% in the First Half of 2019
2019-07-09 07:00:00 | Catalent Extends Global Commercial Spray Drying Capabilities in Europe
2019-06-27 07:00:00 | Novavax selling manufacturing business amid good news for flu vaccine
2019-06-24 14:56:00 | Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027
2019-06-23 16:10:53 | Did Hedge Funds Drop The Ball On Catalent Inc CTLT ?
2019-06-19 09:00:01 | Catalent CTLT Upgraded to Buy: What Does It Mean for the Stock?
2019-06-19 06:59:00 | Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
2019-06-10 08:06:38 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-30 16:15:00 | Catalent, Inc. to Present at the Jefferies Healthcare Conference
2019-05-30 08:04:59 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-28 08:05:07 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-21 08:52:12 | Catalent Acquires Gene Therapy Leader Paragon Bioservices
2019-05-08 08:31:01 | Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT
2019-05-07 14:23:34 | Catalent Inc CTLT Q3 2019 Earnings Call Transcript
2019-05-07 08:55:12 | Catalent CTLT Surpasses Q3 Earnings Estimates
2019-05-07 08:03:34 | See what the IHS Markit Score report has to say about Catalent Inc.
2019-05-07 07:45:36 | Catalent: Fiscal 3Q Earnings Snapshot
2019-05-07 07:30:00 | Catalent, Inc. Reports Third Quarter Fiscal 2019 Results
2019-04-30 10:32:02 | Catalent CTLT Earnings Expected to Grow: What to Know Ahead of Next Week's Release
2019-04-24 10:52:31 | Did Hedge Funds Drop The Ball On Catalent Inc CTLT ?
2019-04-15 15:33:27 | Catalent seeks slice of gene therapy market with Paragon buy